144 related articles for article (PubMed ID: 15237851)
1. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen.
Terashima I; Suzuki N; Shibutani S
Cancer Res; 1999 May; 59(9):2091-5. PubMed ID: 10232593
[TBL] [Abstract][Full Text] [Related]
3. Translesion synthesis past tamoxifen-derived DNA adducts by human DNA polymerases eta and kappa.
Yasui M; Suzuki N; Laxmi YR; Shibutani S
Biochemistry; 2006 Oct; 45(39):12167-74. PubMed ID: 17002316
[TBL] [Abstract][Full Text] [Related]
4. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
6. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
7. Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots.
Liapis E; McLuckie KI; Lewis PD; Farmer PB; Brown K
Nucleic Acids Res; 2008 Oct; 36(18):5933-45. PubMed ID: 18805907
[TBL] [Abstract][Full Text] [Related]
8. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes.
Kim SY; Suzuki N; Santosh Laxmi YR; Rieger R; Shibutani S
Chem Res Toxicol; 2003 Sep; 16(9):1138-44. PubMed ID: 12971802
[TBL] [Abstract][Full Text] [Related]
9. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
10. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
Williams-Brown MY; Salih SM; Xu X; Veenstra TD; Saeed M; Theiler SK; Diaz-Arrastia CR; Salama SA
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):78-86. PubMed ID: 21600284
[TBL] [Abstract][Full Text] [Related]
11. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers.
Kim SY; Laxmi YR; Suzuki N; Ogura K; Watabe T; Duffel MW; Shibutani S
Drug Metab Dispos; 2005 Nov; 33(11):1673-8. PubMed ID: 16099924
[TBL] [Abstract][Full Text] [Related]
12. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
[TBL] [Abstract][Full Text] [Related]
13. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
[TBL] [Abstract][Full Text] [Related]
14. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.
Nagy E; Gajjar KB; Patel II; Taylor S; Martin-Hirsch PL; Stringfellow HF; Martin FL; Phillips DH
Br J Cancer; 2014 Jun; 110(12):2874-80. PubMed ID: 24853176
[TBL] [Abstract][Full Text] [Related]
17. Preparation of oligodeoxynucleotides containing a diastereoisomer of alpha-(N(2)-2'-deoxyguanosinyl)tamoxifen by phosphoramidite chemical synthesis.
Santosh Laxmi YR; Suzuki N; Dasaradhi L; Johnson F; Shibutani S
Chem Res Toxicol; 2002 Feb; 15(2):218-25. PubMed ID: 11849048
[TBL] [Abstract][Full Text] [Related]
18. Accomodation of S-cis-tamoxifen-N(2)-guanine adduct within a bent and widened DNA minor groove.
Shimotakahara S; Gorin A; Kolbanovskiy A; Kettani A; Hingerty BE; Amin S; Broyde S; Geacintov N; Patel DJ
J Mol Biol; 2000 Sep; 302(2):377-93. PubMed ID: 10970740
[TBL] [Abstract][Full Text] [Related]
19. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo.
Moorthy B; Sriram P; Randerath E; Randerath K
Biochem Pharmacol; 1997 Mar; 53(5):663-9. PubMed ID: 9113085
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen.
Shibutani S; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Chem Res Toxicol; 1999 Jul; 12(7):646-53. PubMed ID: 10409405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
